FDA fast track designation granted to Zentylor for Progressive Supranuclear Palsy (PSP)
Noscira announced that the FDA has granted fast track designation to its neuroprotector drug, Zentylor (tideglusib) for the treatment of Progressive Supranuclear Palsy (PSP). The Phase 2 trial for Progressive Supranuclear Palsy (PSP) commenced in December 2009 and is currently in progress. Additionally, in November of 2009, Noscira announced that the FDA had granted Zentylor orphan drug status for treating PSP.
Zentylor is a GSK-3 inhibitor in clinical development for PSP.
For more information please visit www.noscira.com.